MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights

🏆 Market Movers – Top 5 Brands by Value

Key Takeaway: GI and Anti-Diabetic therapies are dominating value and growth. Alkem is out-executing everyone.

📊 Therapy Area Heatmap – What’s Winning?

🧪 Gastrointestinal (GI) – Booming

• PAN / PAN D (Alkem): Double-digit growth + high EI = consistent wins.
• LIV.52 (Himalaya): Ayurvedic anchor brand still thriving.
• UDILIV (Abbott) & ELECTRAL (FDC): Solid backup growth players.

Strategic Call: GI is a goldmine. Alkem owns the narrative; others need niche innovation or value-based expansion.

📉 Anti-Diabetics – Evolving Fast

• RYZODEG (Abbott–Novo Nordisk): 💨 31.7% growth | EI: 126% → Top disruptor
• Glycomet GP (USV): Strong base brand | Steady performer
• Mixtard (Novo Nordisk): -7.9% drop | EI: 88% → Legacy brand fatigue

Strategic Call: Modern insulins are on the rise. Rethink brand lifecycle.

🪠 Anti-Infectives (AI) – Flat but Stable

• Augmentin (GSK): Value leader, but declining.
• Clavam (Alkem): Rising challenger with solid momentum.
• Monocef (Aristo): Minimal growth.

Strategic Call: Defensive play now. Focus on resistance positioning or pediatric/new indication pivots.

❤️ Cardiac – Consistent and Under the Radar

• Telma (Glenmark), CILACAR (JB Chemicals), ECOSPRIN AV (USV): All steady with ~8–18% growth.

Strategic Call: Solid revenue but needs innovation. Opportunity in fixed-dose combos and remote patient monitoring tie-ins.

🧠 Neuro/CNS & Others – Small, but Sticky

• LEVIPIL (Sun): CNS staple with 8.9% growth.
• THYRONORM (Abbott) & MANFORCE (Mankind): Reliable performers with brand loyalty.

💼 Corporate-Level Strategic Insights

📅 Alkem: The Category King

• 3 blockbuster brands (PAN, PAN D, CLAVAM).
• Dominating both GI & Anti-Infectives.
• High EI + High Incr Gain = textbook execution.

🔬 Abbott: Balanced Portfolio Mastery

• Targeted bets across GI, Diabetes, Hormones.
• RYZODEG leads the charge; THYRONORM & UDILIV keep the base strong.

🏢 GSK: Needs a Refresh

• Augmentin is still #1 but eroding. Needs lifecycle innovation or value-based repositioning.

⛰ Himalaya: Herbal Hustler

• LIV.52 is outperforming many modern brands.
• Proof that brand heritage + trust can win in a crowded market.

🧬 Novo Nordisk: A Tale of Two Insulins

• Mixtard declining. RYZODEG scaling fast.
• Push RYZODEG harder, sunset Mixtard with grace.

📌 Final Word: What Should Brand Managers Do Now?

• ✅ Double down on fast-growing therapies (GI, Diabetes)
• 🔄 Reallocate from legacy brands to innovation-rich molecules
• 🔍 Use Evolution Index (EI) as a true north—more than just growth, it shows outperformance

🗺️ Regional + Therapy Drilldowns: Where’s the Action?

Regional lens across the top therapy areas. Here’s where brand performance is peaking:

South India:

• GI Dominance: PAN, PAN D, and LIV.52 clock highest incremental gains in metros like Chennai, Hyderabad.
• Cardiac Clarity: CILACAR and ECOSPRIN AV performing steadily in Tier 2 belts of Kerala and Karnataka.

North India:

• Diabetes Hotbed: RYZODEG and Glycomet GP see strong adoption in Punjab, Delhi NCR.
• Anti-Infectives Uptick: Clavam showing a spike in prescribing patterns across Haryana and UP.

West India:

• Herbal Edge: LIV.52 gets traction across Maharashtra; also strong Chemist recall in Mumbai.
• Neuro Momentum: LEVIPIL holding steady in metros with high CNS load.

East + North-East:

• Growth Frontier: ELECTRAL and UDILIV expanding penetration via government procurement and semi-urban outreach.

Strategic Call: Regional focus = smarter allocation. Custom marketing mixes to maximize traction.

📎 Sources & Methodology

• Primary data: IQVIA & PharmaTrac – March 2025 retail & prescription audit data
• Regional insights: SMSRC (South Asia Market Survey & Research Center) zone-wise Rx trends
• Strategic commentary: Derived from company investor presentations, annual reports, and media publications (ET Healthworld, Mint Health, Business Standard)

A MedicinManAI Feature